Advertisement

Analytical and Bioanalytical Chemistry

, Volume 397, Issue 1, pp 161–171 | Cite as

Development of an LC–MS/MS method for analysis of interconvertible Z/E isomers of the novel anticancer agent, Bp4eT

Original Paper

Abstract

This study was focused on a liquid chromatography/tandem mass spectrometry (LC/MS/MS) method development for quantification of a novel potential anticancer agent, 2-benzoylpyridine 4-ethyl-3-thiosemicarbazone (Bp4eT), in aqueous media. Solid Bp4eT was found to consist predominantly of the Z isomer, while in aqueous media, both isomers coexist. Sufficient separation of both isomers was achieved on a Synergi 4u Polar RP column with a mobile phase composed of 2 mM ammonium formate, acetonitrile, and methanol (30:63:7; v/v/v). The photo diode array analysis of both isomers demonstrated different absorption spectra which hindered UV-based quantification. However, an equal and reproducible response was found for both isomers using an MS detector, which enables the determination of the total content of Bp4eT (i.e., both E− and Z− isomeric forms) by summation of the peak areas of both isomers. 2-Hydroxy-1-naphthylaldehyde 4-methyl-3-thiosemicarbazone (N4mT) was selected as the internal standard. Quantification was performed in selective reaction monitoring using the main fragments of [M+H]+ (240 m/z for Bp4eT and 229 m/z for N4mT). The method was validated over 20–600 ng/ml. This procedure was applied to a preformulation study to determine the proper vehicle for parenteral administration. It was found that Bp4eT was poorly soluble in aqueous media. However, the solubility can be effectively improved using pharmaceutical cosolvents. In fact, a 1:1 mixture of PEG 300/0.14 M saline markedly increased solubility and may be a useful drug formulation for intravenous administration. This investigation further accelerates development of novel anticancer thiosemicarbazones. The described methods will be useful for analogs currently under development and suffering the same analytical issue.

Figure

Chromatogram of the LC-MS/MS analysis of Bp4eT; UV absorption spectra of both Bp4eT isomers.

Keywords

2-Benzoylpyridine 4-ethyl-3-thiosemicarbazone Bp4eT LC–MS Isomer Solubility 

Notes

Acknowledgements

This study was supported by the grant of Ministry of Education, Youth, and Sport of the Czech Republic MSM 0021620822. D.R.R. and D.S.K. thank the National Health and Medical Research Council for grant and fellowship support.

References

  1. 1.
    Yu Y, Wong J, Lovejoy DB, Kalinowski DS, Richardson DR (2006) Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res 12:6876–6883CrossRefGoogle Scholar
  2. 2.
    Richardson DR, Kalinowski DS, Lau S, Jansson PJ, Lovejoy DB (2009) Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta 1790:702–717CrossRefGoogle Scholar
  3. 3.
    Yu Y, Kalinowski DS, Kovacevic Z, Siafakas AR, Jansson PJ, Stefani C, Lovejoy DB, Sharpe PC, Bernhardt PV, Richardson DR (2009) Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem 52:5271–5294CrossRefGoogle Scholar
  4. 4.
    Buss JL, Torti FM, Torti SV (2003) The role of iron chelation in cancer therapy. Curr Med Chem 10:1021–1034CrossRefGoogle Scholar
  5. 5.
    Tam TF, Leung-Toung R, Li W, Wang Y, Karimian K, Spino M (2003) Iron chelator research: past, present, and future. Curr Med Chem 10:983–995CrossRefGoogle Scholar
  6. 6.
    Schelman WR, Morgan-Meadows S, Marnocha R, Lee F, Eickhoff J, Huang W, Pomplun M, Jiang Z, Alberti D, Kolesar JM, Ivy P, Wilding G, Traynor AM (2009) A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemother Pharmacol 63:1147–1156CrossRefGoogle Scholar
  7. 7.
    Nutting CM, van Herpen CM, Miah AB, Bhide SA, Machiels JP, Buter J, Kelly C, de Raucourt D, Harrington KJ (2009) Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma. Ann Oncol 20:1275–1279CrossRefGoogle Scholar
  8. 8.
    Sah P (1954) Nicotinyl and isonicotinyl hydrazones of pyridoxal. J Am Chem Soc 76:300CrossRefGoogle Scholar
  9. 9.
    Richardson DR, Tran EH, Ponka P (1995) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86:4295–4306Google Scholar
  10. 10.
    Yuan J, Lovejoy DB, Richardson DR (2004) Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 104:1450–1458CrossRefGoogle Scholar
  11. 11.
    Whitnall M, Howard J, Ponka P, Richardson DR (2006) A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A 103:14901–14906CrossRefGoogle Scholar
  12. 12.
    Kovarikova P, Mrkvickova Z, Klimes J (2008) Investigation of the stability of aromatic hydrazones in plasma and related biological material. J Pharm Biomed Anal 47:360–370CrossRefGoogle Scholar
  13. 13.
    Kalinowski DS, Yu Y, Sharpe PC, Islam M, Liao YT, Lovejoy DB, Kumar N, Bernhardt PV, Richardson DR (2007) Design, synthesis, and characterization of novel iron chelators: structure–activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents. J Med Chem 50:3716–3729CrossRefGoogle Scholar
  14. 14.
    Kovarikova P, Klimes J, Sterba M, Popelova O, Gersl V, Ponka P (2006) HPLC determination of a novel aroylhydrazone iron chelator (o-108) in rabbit plasma and its application to a pilot pharmacokinetic study. J Chromatogr B 838:107–112CrossRefGoogle Scholar
  15. 15.
    Kovarikova P, Klimes J, Sterba M, Popelova O, Mokry M, Gersl V, Ponka P (2005) Development of high-performance liquid chromatographic determination of salicylaldehyde isonicotinoyl hydrazone in rabbit plasma and application of this method to an in vivo study. J Sep Sci 28:1300–1306CrossRefGoogle Scholar
  16. 16.
    Feun L, Modiano M, Lee K, Mao J, Marini A, Savaraj N, Plezia P, Almassian B, Colacino E, Fischer J, MacDonald S (2002) Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule. Cancer Chemother Pharmacol 50:223–229CrossRefGoogle Scholar
  17. 17.
    Mrkvickova Z, Kovarikova P, Klimes J, Kalinowski D, Richardson DR (2007) Development and validation of HPLC-DAD methods for the analysis of two novel iron chelators with potent anti-cancer activity. J Pharm Biomed Anal 43:1343–1351CrossRefGoogle Scholar
  18. 18.
    Stariat J, Kovarikova P, Klimes J, Lovejoy DB, Kalinowski DS, Richardson DR (2009) HPLC methods for determination of two novel thiosemicarbazone anti-cancer drugs (N4mT and Dp44mT) in plasma and their application to in vitro plasma stability of these agents. J Chromatogr B 877:316–322CrossRefGoogle Scholar
  19. 19.
    Lovejoy DB, Richardson DR (2002) Novel “hybrid” iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. Blood 100:666–676CrossRefGoogle Scholar
  20. 20.
    Zhao Y, Sukbuntherng J (2005) Simultaneous determination of Z-3-[(2, 4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone (SU5416) and its interconvertible geometric isomer (SU5886) in rat plasma by LC/MS/MS. J Pharm Biomed Anal 38:479–486CrossRefGoogle Scholar
  21. 21.
    CDER and CVM (2001) Bioanalytical method validation, guidance for industry. http://www.fda.gov/cder/guidance/4252fnl.htm
  22. 22.
    Bonfiglio R, King RC, Olah TV, Merkle K (1999) The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Commun Mass Spectrom 13:1175–1185CrossRefGoogle Scholar
  23. 23.
    Richardson DR, Sharpe PC, Lovejoy DB, Senaratne D, Kalinowski DS, Islam M, Bernhardt PV (2006) Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J Med Chem 49:6510–6521CrossRefGoogle Scholar
  24. 24.
    Bernhardt PV, Wilson GJ, Sharpe PC, Kalinowski DS, Richardson DR (2008) Tuning the antiproliferative activity of biologically active iron chelators: characterization of the coordination chemistry and biological efficacy of 2-acetylpyridine and 2-benzoylpyridine hydrazone ligands. J Biol Inorg Chem 13:107–119CrossRefGoogle Scholar
  25. 25.
    Holcapek M, Kolarova L, Nobilis M (2008) High-performance liquid chromatography–tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites. Anal Bioanal Chem 391:59–78CrossRefGoogle Scholar
  26. 26.
    Broadhead (2004) In: Gibson M (ed) Pharmaceutical preformulation and formulation a practical guide form candidate drug selection to commercial dosage form. CRC, Boca RatonGoogle Scholar
  27. 27.
    Mottu F, Laurent A, Rufenacht DA, Doelker E (2000) Organic solvents for pharmaceutical parenterals and embolic liquids: a review of toxicity data. PDA J Pharm Sci Technol 54:456–469Google Scholar
  28. 28.
    Kovarikova P, Mokry M, Klimes J, Vavrova K (2006) HPLC study on stability of pyridoxal isonicotinoyl hydrazone. J Pharm Biomed Anal 40:105–112CrossRefGoogle Scholar
  29. 29.
    Krishna G, Mao J, Almassian B, Lang W (1999) Development of a parenteral formulation of an investigational anticancer drug, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone. Pharm Dev Technol 4:71–80Google Scholar
  30. 30.
    University of Iowa, AR, Institutional Animal Care and Use Committee. Blood collection and administration of fluids and drugs (mouse). http://research.uiowa.edu/animal/?get=mse_tech

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Department of Pharmaceutical Chemistry and Drug Control, Faculty of Pharmacy in Hradec KrálovéCharles University in PragueHradec KrálovéCzech Republic
  2. 2.Iron Metabolism and Chelation Program, Department of Pathology and Bosch Institute, Blackburn BuildingUniversity of SydneySydneyAustralia

Personalised recommendations